AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04552548 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: regional nerve block
Description: Abdominal field blocks have been used in anesthesia for surgery involving the anterior abdominal wall with ultrasound-guided technique. TAP block is a regional anesthetic technique that blocks neural afferents of the anterolateral abdominal wall. Using anatomical landmark guidance or with the aid of ultrasound (US), local anesthetic is injected into the transversus abdominis fascial plane, where the nerves from T6 to L1 are located. Ultrasound-guided quadratus lumborum (QL) block is considered now as one of the novel truncal abdominal blocks, as it is effective in preventing somatic pain associated with upper and lower abdominal surgeries.
Study NCT02584387 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 3D Video Virtual Reality Exposure Therapy
Description: The 3D video exposure therapy treatment will be administered using an oculus rift virtual reality headset. The oculus rift is a new, affordable virtual reality headset, which uses two different spherical lenses to induce a sense of stereoscopic 3D. Ortho-stereoscopic 3D refers to 3D videos that are designed to mimic the natural depth we normally see, as opposed to exaggerating it (i.e. Commercial 3D movies). To create these 3D videos, the UT 3D Department shot videos of live spiders using a stereoscopic 3D dual camera rig, which simultaneously shoots footage with two cameras positioned apart from each other in a way that mimics the natural pupillary distance between our right and left eyes. To create a sense of 3D depth, the footage of the right and left cameras is then projected on the two different lenses of the oculus rift, creating a sense of depth to the viewer through retinal disparity.
Study NCT03189654 — intervention group
Intervention type: DEVICE
Intervention: Non-invasive ventilation
Description: Non-invasive Ventilation for a Minimum of 8 h per day after pleurocentesis
Study NCT03980717 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Goldbal Detachable Balloon and delivery microcatheter
Description: Between 28+0/7 - 31+6/7 weeks gestation for severe CDH placement of the detachable balloon. Balloon retrieval will be planned for no later than 36+6/7 weeks at the discretion of the FETO center.
Study NCT04710914 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prolonged sedation with isoflurane
Description: Adult patients admitted to the surgical intensive care unit at the Rouen University Hospital for septic shock and requiring sedation for more than 3 days and a maximum of 10 days will be randomised in two groups.~The experimental group will receive sedation by inhaled isoflurane The control group will receive sedation by intravenous midazolam
Study NCT04710914 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prolonged sedation with midazolam
Description: Adult patients admitted to the surgical intensive care unit at the Rouen University Hospital for septic shock and requiring sedation for more than 3 days and a maximum of 10 days will be randomised in two groups.~The experimental group will receive sedation by inhaled isoflurane The control group will receive sedation by intravenous midazolam
Study NCT02916459 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 21G EBUS-TBNA needle
Study NCT02916459 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Flexible 19G EBUS-TBNA needle
Study NCT01439126 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: clonidine hydrochloride
Description: KAPVAY™ (clonidine hydrochloride) 0.1 mg, 0.2 mg, 0.3 mg, or 0.4 mg from Weeks 11-36
Study NCT01439126 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: KAPVAY™ (clonidine hydrochloride) 0.1 mg, 0.2 mg, or 0.3 mg at Week 11; KAPVAY™ 0.1 mg, KAPVAY™ 0.2 mg, or placebo at Week 12; KAPVAY™ 0.1 mg or placebo at Week 13; placebo from Weeks 14-36
Study NCT03720600 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MAB Intervention
Description: The intervention is a 60-minute voice-recorded PowerPoint presentation on a mindfulness- and acceptance-based (MAB) intervention adapted from Eustis et al. (2017). This adaptation was informed by research on MAB therapies and other approaches to coping with discrimination (e.g., Watson, Black, \& Hunter, 2016), as well as clinical experience providing an in-person workshop on MAB strategies for coping with racism-related stress.
Study NCT03720600 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: MAB Intervention
Description: The intervention is a 60-minute voice-recorded PowerPoint presentation on a mindfulness- and acceptance-based (MAB) intervention adapted from Eustis et al. (2017). This adaptation was informed by research on MAB therapies and other approaches to coping with discrimination (e.g., Watson, Black, \& Hunter, 2016), as well as clinical experience providing an in-person workshop on MAB strategies for coping with racism-related stress.
Study NCT03039894 — intervention group
Intervention type: OTHER
Intervention: Gradebook Game
Description: Students in the intervention group will spend time meeting as teams to review their scorecards, and do team-building activities, all of which will occur during non-content periods at school (Advisory and Enrichment).
Study NCT03388619 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADT
Description: After enrollment if clinically indicated (i.e., anti-androgen, gonadotropin releasing hormone agonist, or combination of both).
Study NCT02203656 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone
Description: Testosterone injection
Study NCT03033056 — intervention group
Intervention type: BEHAVIORAL
Intervention: Test of fear conditioning
Description: Behavioral and brain correlates of conditioned fear generalization and avoidance will be assessed using fMRI and related to levels of anxiety related psychopathology.
Study NCT01498614 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Affect School and Basal body awareness
Description: Affect School is an educational method based on SS Tomkins affect theory and Basal Body Awareness therapy is an educational stress reducing method
Study NCT02168985 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TFH program
Description: The Faithful House (TFH), is a three-day faith-based skills-building curriculum. The curriculum aims to increase household resilience by strengthening families and couples' relationships through enhanced couple communication
Study NCT04400578 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Trichloroacetic acid 85% (TCA)
Description: Purpose and scope of Medical Device: Treatment and relief of a disease. Application to cervical intraepithelial neoplasia with a cotton swab.TCA is an investigational device intended to achieve a complete histologic remission in individuals with cervical intraepithelial neoplasia (CIN) grade 1/2.
Study NCT00566865 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo for gemfibrozil
Description: mitiglinide + placebo for gemfibrozil 600 mg bid
Study NCT00566865 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemfibrozil
Description: Mitiglinide + 600 mg gemfibrozil bid
Study NCT02968914 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Benralizumab
Description: A humanized, afucosylated, monoclonal antibody (mAb) that binds specifically to the human IL-5 receptor alpha subunit (IL-5Rα) on the target cell.
Study NCT02968914 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Benralizumab
Description: A humanized, afucosylated, monoclonal antibody (mAb) that binds specifically to the human IL-5 receptor alpha subunit (IL-5Rα) on the target cell.
Study NCT03776773 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pollution exposure
Description: Pollution exposure and sleep data will be recorded by pollution sensor and polysomnography respectively. In order to compare the variations according to the pollinisation season and the allergic rhinitis status of the patients.
Study NCT02526888 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACT-541468
Description: Oral capsule (25 mg) as single dose
Study NCT02526888 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diltiazem
Description: Two oral capsules (2 x 120 mg) once daily from Day 1 to Day 7
Study NCT03776773 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Pollution exposure
Description: Pollution exposure and sleep data will be recorded by pollution sensor and polysomnography respectively. In order to compare the variations according to the pollinisation season and the allergic rhinitis status of the patients.
Study NCT01498614 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Affect School and Basal body awareness
Description: Affect School is an educational method based on SS Tomkins affect theory and Basal Body Awareness therapy is an educational stress reducing method
Study NCT00548444 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA85A
Description: Vaccine. Dose: 1 x 10\^8 plaque-forming units (pfu) given by intradermal injection into the deltoid region of the upper arm.
Study NCT01139450 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0417
Description: Topical 0417 test product applied twice daily for 4 weeks
Study NCT01139450 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle of 0417 test product
Description: Vehicle of 0417 test product applied twice daily for 4 weeks
Study NCT00548444 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Deuterated glucose infusion
Description: 6,6D2-glucose given as a timed intravenous infusion. The total dose of deuterated glucose will be 1g/kg volunteer body weight (up to a maximum of 60g).
Study NCT00690807 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PH-10
Description: PH-10 will be applied daily for 28 days to skin areas affected by atopic dermatitis.
Study NCT02995044 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY987521
Description: Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application. (Formulation Code: Z09-180)
Study NCT02995044 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPF Control
Description: Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application.
Study NCT01139450 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus Ointment 0.03%
Description: Reference product for 0417 test product. Apply twice daily for 4 weeks
Study NCT01462721 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: eSVS® Mesh
Description: Patients with multi-vessel coronary artery disease who require saphenous vein graft (SVG) coronary artery bypass graft (CABG) surgery of the Right coronary Artery (RCA) and the Circumflex Artery (Cx) due to atherosclerotic coronary artery disease will serve as their own control. They will be randomized to either an SVG+eSVS Mesh to the RCA and an SVG to the Cx or an SVG to the RCA and an SVG+eSVS Mesh to the Cx.
Study NCT03068273 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Real-time CGM data
Study NCT00494910 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Meaning Centered Group Psychotherapy
Description: this eight-week (1 ½ hour weekly sessions) Session 1 - Concepts of Meaning and Sources of Meaning Session 2 - Cancer and Meaning Session 3 - Meaning and Historical Context of Life Session 4 - Storytelling, Legacy Project (optional) Session 5 - Limitations and Finiteness of Life Session 6 - Responsibility, Creativity, Deeds Session 7 - Experience, Nature, Art, Humor Session 8 - Transitions, Goodbyes, Hopes for the Future
Study NCT00494910 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Supportive Group Psychotherapy
Description: The eight weekly 1 ½ hour sessions will focus on group discussion on a set of specific themes that emerge for patients coping with cancer. The session themes or topics will include such issues as: the discussion of strategies for coping with medical issues and procedures, communication with health care providers and issues related to family, friends, and occupational life.
Study NCT01211366 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cell Saver RBCs
Description: Use of cell saver RBCs to decrease the infusion of allogeneic PRBCs, crystalloid, and colloid in post-operative infants following CPB as needed for hemodynamic instability
Study NCT04352855 — intervention group
Intervention type: DRUG
Intervention: Ceftolozane/tazobactam
Description: Administration
Study NCT00966602 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-809
Description: VX-809 capsule, once daily for 14 days
Study NCT00966602 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-770
Description: VX-770 tablet, once every 12 hours for 14 days
Study NCT01211366 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional volume infusion
Description: Infusion of allogeneic PRBCs, crystalloid, and colloid as needed for hemodynamic instability
Study NCT03010358 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entospletinib
Description: Given PO
Study NCT03010358 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03010358 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Given IV
Study NCT03010358 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT00966602 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-809 & VX-770
Description: VX-809 capsule, once daily, and VX-770 tablets, once every 12 hours, for 14 days
Study NCT00966602 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching Placebo
Study NCT04022720 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Platelet Rich Fibrin Application
Description: Platelet Rich Fibrin application at first post-op visit.
Study NCT04345575 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PainCare VR
Description: Didactic content delivered in virtual reality to support participants in learning cognitive and behavioral self-management skills based on cognitive-based therapy, biofeedback, and mindfulness strategies for pain management.
Study NCT04345575 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Audio content
Description: The audio program consisted of the majority of the same narrative content contained in the VR program. Owing to VR having a visual and auditory media form, about one-third of the VR program could not be included in the audio. Participants accessed 21 audio recordings on SoundCloud and asked to complete one session each day.
Study NCT01763437 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tetracycline
Description: Chalazia randomized to the treatment arm will be injected with 0.05 mL of 2% tetracycline solution.
Study NCT02478658 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise training
Description: high-intensity resistance training
Study NCT00784836 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BG9418 (interferon beta 1-a)
Study NCT03943394 — intervention group
Intervention type: OTHER
Intervention: fresh samples are obtained from patients for detction of PCM1- JAK2 fusion gene
Description: Samples are dehydrated in ethanol (a 50, 80 and 95% (v/v) series, exposure for 3 min to 300 µl ethanol at each concentration) prior to hybridization.~Samples on tapes are hybridized for 15 minutes at 55?C using a moisture-sealed slide incubation chamber. Briefly, 500 µl volumes of hybridization buffer (0.7 M NaCl, 0.1 M Tris \[pH 8.0\], 0.1% sodium dodecyl sulfate, 10 mM EDTA, containing probe, preheated to 55 ºC) are applied to the surface of the tape and the chamber's lid is sealed, creating a moist, temperature controlled environment within the chamber.~After 15 min, the lid is removed and samples are briefly rinsed with probe-free hybridization buffer, preheated to 55ºC.~Hybridized cells on tapes are counterstained for 10 minutes in the dark with \~30 µl mounting medium containing 1.5 µg ml-1 4',6-diamidino-2-phenylindole (DAPI).~Then tapes are mounted with a coverslip and examined using a fluorescence microscope.
Study NCT02320591 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: care management fee
Description: for each Medicare beneficiary attributed to the practice, the practice received a monthly care management fee
Study NCT01908257 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lesinurad 400 mg
Study NCT02320591 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: feedback reports
Description: Each participating practice received quarterly reports showing the practice's trend in key outcomes during the pre-intervention and intervention periods. The risk adjusted average Medicare expenditures of their patients were also shown in relation to all of the other CPC practices in their region, and to those with a similar average risk profile. Unadjusted hospitalization rates and emergency room visits were also plotted over time and compared to those of other CPC practices in the region
Study NCT02320591 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: technical assistance
Description: CPC practices could ask for technical assistance on transformation activities from a regional learning faculty (RLF). The RLF also provided seminars and other learning activities, as well as provided a forum for participating practices to share lessons they had learned.
Study NCT00464126 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 5% albumin
Description: 5% albumin in 10cc/kg aliquots for postoperative volume resuscitation
Study NCT00464126 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: crystalloid
Description: saline in 10cc/kg aliquots for postoperative volume resuscitation
Study NCT02892591 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabis
Description: vaporized plant material
Study NCT06405256 — intervention group
Intervention type: RADIATION
Intervention: magnetic resonance imaging-guided adaptive radiotherapy
Description: Stereotactic Radiotherapy (with the prescribed dose of PTV 52-52.5 Gy, 13-15 fractions and Boost (if any) 60Gy, 15 fractions)
Study NCT03859115 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TENS (transcutaneous electrical nerve stimulation)
Description: transcutaneous nerve stimulation with electrical pulse generation
Study NCT03859115 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TENS (transcutaneous electrical nerve stimulation)
Description: transcutaneous nerve stimulation with electrical pulse generation
Study NCT02892591 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone
Description: oral capsule
Study NCT03859115 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: sham intervention
Description: sham stimulation without electrical pulse generation
Study NCT03859115 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: sham intervention
Description: sham stimulation without electrical pulse generation
Study NCT01226186 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Nurse dispensed oral morphine.
Description: Nurse will dispense oral morphine on request from the patient.
Study NCT01226186 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Patient self medication of oral morphine.
Description: Patients will self medicate their oral morphine pain control solution following surgery.
Study NCT04527627 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nursing Empowerment Intervention
Description: Nursing empowerment intervention The intervention will be carried out during the ICU discharge planning. A Patient Information Guide for Intensive Care Unit patients will be developed.~The guide will be based on the findings obtained in a previous qualitative study and on previous studies on patient empowerment and education. Its structure will take into account the dimensions of empowerment: bio-physiological, functional, social, experience, ethics and the financial aspect. The guide will be reviewed by experts in the development of information guides for patients and family members and will be evaluated by the participating ICUs before use.~EG patients will receive the intervention verbally and in booklet format from the study nurses at each ICU.
Study NCT02636946 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bimatoprost SR
Description: Up to three Bimatoprost SR 15 micrograms (μg) administrations at Day 4, Weeks 16 and 32 (Stage 1) or two Bimatoprost SR 15 μg administrations at Day 4 and Week 16 (Stage 2).
Study NCT02636946 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bimatoprost SR
Description: Up to three Bimatoprost SR 15 micrograms (μg) administrations at Day 4, Weeks 16 and 32 (Stage 1) or two Bimatoprost SR 15 μg administrations at Day 4 and Week 16 (Stage 2).
Study NCT04619563 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib Hydrochloride plus Docetaxel
Description: Anlotinib Hydrochloride (12mg, QD PO d1-14, 21days per cycle) and Docetaxel (75mg/m2 IV d1)